GenomeFrontier Therapeutics
GenomeFrontier develops virus-free gene- and cell-engineering technologies and cell-modified gene therapies. The company focuses on non-viral vector systems and transposon-based integration to produce autologous, gene-modified T cell products (CAR T and TCR T), and pursues preclinical and early clinical development in collaboration with academic and industry partners.
Industries
Nr. of Employees
small (1-50)
GenomeFrontier Therapeutics
Patents
Products
GF-CART01
Non-viral autologous CAR T cell therapy developed using virus-free gene- and cell-engineering platforms; in Phase I clinical evaluation for B cell malignancies.
GF-CART02
Multiplex armored dual-targeting autologous CAR T cell therapy in preclinical development for multiple myeloma; subject of animal PK/PD and safety studies.
GF-CART03
Non-viral autologous CAR T product candidate being developed for certain solid tumors (including glioblastoma) with supporting preclinical collaborations.
qCART
A virus-free Quantum Engine for developing CAR T cell therapy that synergistically integrates four platforms for rapid and cost-effective manufacturing of clinical-scaled CAR T cells.
Quantum Engine
A robust cell-engineering system leveraging four proprietary virus-free gene and cell engineering platforms to potentially cure a wide range of diseases including cancer.
iCellar
A proprietary cell expansion platform composed of agents and/or gene-modified cells designed to enhance cell expansion capacity while maintaining cell quality and stemness for clinical-scale cell therapy.
GF-CART01
Non-viral autologous CAR T cell therapy developed using virus-free gene- and cell-engineering platforms; in Phase I clinical evaluation for B cell malignancies.
GF-CART02
Multiplex armored dual-targeting autologous CAR T cell therapy in preclinical development for multiple myeloma; subject of animal PK/PD and safety studies.
GF-CART03
Non-viral autologous CAR T product candidate being developed for certain solid tumors (including glioblastoma) with supporting preclinical collaborations.
qCART
A virus-free Quantum Engine for developing CAR T cell therapy that synergistically integrates four platforms for rapid and cost-effective manufacturing of clinical-scaled CAR T cells.
Quantum Engine
A robust cell-engineering system leveraging four proprietary virus-free gene and cell engineering platforms to potentially cure a wide range of diseases including cancer.
iCellar
A proprietary cell expansion platform composed of agents and/or gene-modified cells designed to enhance cell expansion capacity while maintaining cell quality and stemness for clinical-scale cell therapy.
Services
Preclinical production of cell therapy material and execution of animal safety, efficacy, PK/PD, and histopathology studies in partnership with academic centers.
Exploratory projects to enhance cell therapy manufacturing workflows and capacity, including grant-supported work with external manufacturing partners.
Partnership-based development of de novo therapeutic protein and target discovery platforms.
Regulatory filing support, CMC strategy, and product development planning informed by prior IND and marketing application experience.
Preclinical production of cell therapy material and execution of animal safety, efficacy, PK/PD, and histopathology studies in partnership with academic centers.
Exploratory projects to enhance cell therapy manufacturing workflows and capacity, including grant-supported work with external manufacturing partners.
Partnership-based development of de novo therapeutic protein and target discovery platforms.
Regulatory filing support, CMC strategy, and product development planning informed by prior IND and marketing application experience.
Expertise Areas
- Virus-free gene therapy development
- Transposon-mediated gene integration
- Autologous CAR T and TCR T cell therapy development
- Preclinical safety and efficacy studies
Key Technologies
- Transposon-based gene integration
- Non-viral vector delivery
- Electroporation and non-viral delivery optimization
- Autologous CAR-T / TCR-T cell engineering
News & Updates
A Phase I clinical study to evaluate safety and preliminary clinical activity of a non-viral autologous CAR T therapy for B cell malignancies.
Awarded a G-Rex grant (in collaboration with external manufacturing partners) to support exploratory studies aimed at enhancing manufacturing of a non-viral autologous CAR T therapy.
Research collaboration with an academic partner to develop multiplex CAR-T constructs for epithelial solid cancers with large transgene sizes.
A Phase I clinical study to evaluate safety and preliminary clinical activity of a non-viral autologous CAR T therapy for B cell malignancies.
Awarded a G-Rex grant (in collaboration with external manufacturing partners) to support exploratory studies aimed at enhancing manufacturing of a non-viral autologous CAR T therapy.
Research collaboration with an academic partner to develop multiplex CAR-T constructs for epithelial solid cancers with large transgene sizes.